- Home
- TGTX vs LPL Comparison
TGTX vs LPL Comparison
Compare TGTX & LPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- LPL
- Stock Information
- Founded
- TGTX 1993
- LPL 1985
- Country
- TGTX United States
- LPL South Korea
- Employees
- TGTX N/A
- LPL N/A
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- LPL Industrial Machinery/Components
- Sector
- TGTX Health Care
- LPL Technology
- Exchange
- TGTX Nasdaq
- LPL Nasdaq
- Market Cap
- TGTX 4.2B
- LPL 3.4B
- IPO Year
- TGTX 1995
- LPL 2004
- Fundamental
- Price
- TGTX $29.45
- LPL $4.28
- Analyst Decision
- TGTX Strong Buy
- LPL Sell
- Analyst Count
- TGTX 4
- LPL 2
- Target Price
- TGTX $42.50
- LPL N/A
- AVG Volume (30 Days)
- TGTX 2.9M
- LPL 578.4K
- Earning Date
- TGTX 08-04-2025
- LPL 08-14-2025
- Dividend Yield
- TGTX N/A
- LPL N/A
- EPS Growth
- TGTX N/A
- LPL N/A
- EPS
- TGTX 0.36
- LPL N/A
- Revenue
- TGTX $454,069,000.00
- LPL $19,437,582,152.00
- Revenue This Year
- TGTX $84.00
- LPL N/A
- Revenue Next Year
- TGTX $39.26
- LPL $1.04
- P/E Ratio
- TGTX $81.62
- LPL N/A
- Revenue Growth
- TGTX 30.96
- LPL 8.96
- 52 Week Low
- TGTX $21.11
- LPL $2.43
- 52 Week High
- TGTX $46.48
- LPL $4.97
- Technical
- Relative Strength Index (RSI)
- TGTX 42.03
- LPL 58.52
- Support Level
- TGTX $27.23
- LPL $4.29
- Resistance Level
- TGTX $28.85
- LPL $4.44
- Average True Range (ATR)
- TGTX 1.11
- LPL 0.10
- MACD
- TGTX 0.29
- LPL -0.02
- Stochastic Oscillator
- TGTX 99.05
- LPL 32.52
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing, and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in several countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.